European Society for Radiotherapy and Oncology (ESTRO) shared on LinkedIn:
“Long-term results from the RADIOPARP Phase I Trial: safety and radiosensitization of Olaparib with radiotherapy in triple-negative breast cancer patients, published in the Red Journal.
Read it before your patients.”
Title: Safety and potential radiosensitizing effect of Olaparib in combination with breast radiotherapy for TNBC patients with residual disease: long-term results from the RADIOPARP Phase I Trial: Safety and Radiosensitization of Olaparib with Radiotherapy in TNBC.
Journal: Red Journal
Authors: Pierre Loap, Delphine Loirat, Marc-Henri Stern, Jean-Yves Pierga, Kim Cao, Anne Vincent-Salomon, Frederique Berger, Alain Fourquet, Youlia Kirova
More posts featuring ESTRO on OncoDaily.